None listed
Conditions
Brief summary
Acute kidney injury (AKI) occurs in up to two-thirds of patients after lung transplantation, and renal replacement therapy is required in 10%. Amino acid infusion has been shown to reduce AKI in cardiac surgical patients. No trial of amino acid infusion has taken place in lung transplant. The AIRPORT study will determine feasibility of a larger definitive trial and investigate efficacy using markers of kidney function.
Interventions
Balanced amino acid infusion (Synthamin 17 10%) started after induction of anaesthesia and administered by the clinician and continued for 72 hours, until start of renal replacement therapy, or discharge from ICU (whichever comes first). Dose will be 2g/kg ideal body weight/day (to a maximum dose 100g/day). Ideal body weight will be determined with the Devine formula. Intervention will be confirmed on electronic medical record and by research administration staff.
Sponsors
Alfred Health
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All adult patients undergoing lung transplantation
Exclusion criteria
Current or planned dialysis Combined lung and kidney transplant, or combined lung and liver transplant Prior kidney transplant Known allergy to one of the amino acids Congenital abnormality of amino acid metabolism
Outcome results
None listed